3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
3
Phase 3
2
Phase 1
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Hepatocellular
5
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Liver Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urothelial Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Renal Cell
1
Carcinoma
1
Interventions
Gemcitabine
28
Cisplatin
26
Mitomycin
18
BCG Vaccine
12
pembrolizumab
9
Paclitaxel
8
Doxorubicin
7
Docetaxel
7
5-aminolevulinic acid hexyl ester
7
apaziquone
6
Carboplatin
6
vinflunine
5
enfortumab vedotin
5
atezolizumab
5
Vinblastine
5
Radiotherapy
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Fluorouracil
5
Cystectomy
5
durvalumab
4
Surgical Procedures, Operative
4
Nivolumab
4
Transurethral Resection of Bladder
3
Specimen Handling
3
Selenium
3
Radiation
3
Filgrastim
3
Cystoscopy
3
BCG Connaught
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Urinary Bladder Neoplasms
×
tremelimumab
×
Clear all
NCT04960709
2026-04-14
VOLGA
AstraZeneca
Phase 3
Active not recruiting
712 enrolled
NCT03682068
2026-02-03
NILE
AstraZeneca
Phase 3
Active not recruiting
1,246 enrolled